Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent
25 Janeiro 2022 - 6:05PM
Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology
company, today announced the award of another new patent related to
its single-molecule detection assay platform under development. The
USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods,
Systems, and Compositions for Counting Nucleic Acid Molecules.” The
issued claims are directed to detecting a labeled target molecule
on a solid support.
“We have added another important patent to our IP portfolio for
the single-molecule detection platform, which is designed to enable
sequence-free counting of target analytes including cell-free
nucleic acids. We believe this approach may have important
near-term impact in the fields of noninvasive prenatal testing
(NIPT) and liquid biopsy. This latest patent covers key
compositions and methods for labeling target molecules,” said
Matthew Cooper, General Manager, Diagnostics. “This platform has
the potential to greatly reduce operating costs and reduce
turnaround times for genomic tests, with potential utility
extending from nucleic acids to proteins. We are committed to
maximizing the value of our patent portfolio and are actively
assessing partnerships and other approaches that may expedite a
path to market.”
The patent portfolio supporting Progenity’s single-molecule
detection platform includes six distinct patent families covering
different aspects of the molecular counting platform and a separate
family directed to detecting nucleosomal positioning patterns, such
as assessment of cell-free DNA tissue-of-origin. These patents are
part of Progenity’s corporate patent estate consisting of 96 patent
families, including 180 issued patents and more than 220 pending
applications. The portfolio includes patents and applications
directed to methods and devices for drug delivery, methods and
devices for GI sampling and diagnostics, methods and compositions
for treating disease, and molecular and protein tools, assays and
diagnostics.
About ProgenityProgenity, Inc. is a
biotechnology company innovating in the fields of women’s health,
gastrointestinal health and oral biotherapeutics. Progenity applies
a multi-omics approach, combining genomics, epigenomics,
proteomics, and metabolomics to its molecular testing products and
to the development of a suite of investigational ingestible devices
designed to provide precise diagnostic sampling and drug delivery
solutions. Progenity’s vision is to transform healthcare to become
more precise and personal by improving diagnoses of disease and
improving patient outcomes through localized treatment with
targeted therapies.
For more information visit www.progenity.com, or follow the
company on LinkedIn or Twitter.
Forward Looking StatementsThis press release
contains “forward-looking statements,” which statements are subject
to substantial risks and uncertainties and are based on estimates
and assumptions. All statements, other than statements of
historical facts, included in this press release are
forward-looking statements. Forward-looking statements include
statements regarding Progenity’s products under development and the
potential uses for such products in the United States and globally.
In some cases, you can identify forward-looking statements by terms
such as “may,” “might,” “will,” “objective,” “intend,” “should,”
“could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,”
“predict,” “potential,” “develop,” “plan” or the negative of these
terms, and similar expressions, or statements regarding intent,
belief, or current expectations, are forward looking statements.
These statements involve known and unknown risks, uncertainties and
other factors that could cause Progenity’s actual results to differ
materially from the forward-looking statements expressed or implied
in this press release, including Progenity’s ability to
successfully develop and commercialize its products under
development, the uncertainties inherent in the development process,
such as the regulatory approval process, the timing of regulatory
filings, the ability to identify potential partners and other
matters, including the ongoing COVID-19 pandemic, that could affect
sufficiency of existing cash, cash equivalents and short-term
investments to fund operations and the availability or commercial
potential of Progenity’s products, and those risks described in
“Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in Progenity’s
Annual Report on Form 10-K for the year ended December 31, 2020,
filed with the SEC on March 18, 2021, and other subsequent
documents we file with the SEC, including but not limited to
Progenity’s Quarterly Reports on Form 10-Q. Progenity claims the
protection of the Safe Harbor contained in the Private Securities
Litigation Reform Act of 1995 for forward-looking statements.
Progenity expressly disclaims any obligation to update or alter any
statements whether as a result of new information, future events or
otherwise, except as required by law.
Investor Contact:Chuck PadalaManaging Director,
LifeSci Advisorsir@progenity.com (917) 741-7792
Media Contact:Kristin SchaefferCG
Lifemedia@progenity.com (858) 457-2436
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024